Effect of Nivolumab vs Placebo in Patients With Acute Myocardial Infarction: A Randomized Clinical Trial

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

June 15, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

December 31, 2025

Conditions
Acute Anterior ST Segment Elevation Myocardial Infarction
Interventions
DRUG

Nivolumab

Single administration of Nivolumab on the third day of revascularization after acute anterior ST segment elevation myocardial infarction. The active drug Nivolumab will be administered at a standard dose (5mg/kg) dissolved in 100ml 0.9%NaCl solution. Nivolumab was given at a rate of 15-25 drops per minute, and the intravenous infusion time exceeded 1 hour.

OTHER

Placebo

Single administration of Placebo on the third day of revascularization after acute anterior ST segment elevation myocardial infarction. Patients assigned to the placebo treatment group will receive an intravenous infusion of 100 ml 0.9% NaCl solution at a rate of 15-25 drops/min for an IV infusion duration of more than 1 hour.

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

NCT05887830 - Effect of Nivolumab vs Placebo in Patients With Acute Myocardial Infarction: A Randomized Clinical Trial | Biotech Hunter | Biotech Hunter